|Bid||8.20 x 1000|
|Ask||9.74 x 100|
|Day's Range||7.86 - 9.13|
|52 Week Range||7.54 - 22.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.00|
BURLINGAME, Calif., Feb. 01, 2018-- Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today ...
The Burlingame, California-based company said it had a loss of 73 cents per share. Corvus shares have fallen 16 percent since the beginning of the year. The stock has fallen 7.5 percent in the last 12 ...
NEW YORK, NY / ACCESSWIRE / May 8, 2017 / Regulus Therapeutics may not have delivered an impressive first quarter report but shares soared anyway after a change in directors took place. Corvus Pharmaceuticals ...
On a per-share basis, the Burlingame, California-based company said it had a loss of 79 cents. Corvus shares have declined 32 percent since the beginning of the year. The stock has fallen 24 percent in ...
NEW YORK, NY / ACCESSWIRE / April 6, 2017 / Corvus Pharmaceuticals and Neothetics have recently reported some interesting news for investors. Corvus continues to move CPI-444 in FDA clinical trials, while ...
Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) nearly half its value Tuesday following the release of interim results of its Phase 1 study of CPI-444 , designed to treat patients with advanced cancers. Cantor ...
Corvus Pharmaceuticals (CRVS) is a solid momentum stock that has a favorable Zacks Rank and is seeing solid earnings estimate revisions.
Corvus Pharmaceuticals Inc (CRVS) has been on the move lately as the stock has risen by 49.5% in the past four weeks, and it is currently trading well above its 20-Day SMA